Patents by Inventor Toru Miki

Toru Miki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030173203
    Abstract: A pushbutton switch, comprising
    Type: Application
    Filed: September 24, 2002
    Publication date: September 18, 2003
    Applicant: MIYAMA ELECTRIC CO., LTD.
    Inventor: Toru Miki
  • Patent number: 6608181
    Abstract: A novel gene designated as FRAG1 and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: August 19, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Matthew V. Lorenzi, Toru Miki
  • Publication number: 20020032310
    Abstract: A novel gene designated as FRAG1 and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.
    Type: Application
    Filed: August 29, 2001
    Publication date: March 14, 2002
    Applicant: The Govt. of the U.S.A., The Secretary of the Department of Health and Human Services
    Inventors: Matthew V. Lorenzi, Toru Miki
  • Patent number: 6323316
    Abstract: A novel gene designated as FRAG 1 and its encoded protein are disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: November 27, 2001
    Assignee: The United States of America as represented by the Secretary of the Department of and Human Services
    Inventors: Matthew V. Lorenzi, Toru Miki
  • Patent number: 5792638
    Abstract: The oncogene of the present invention, isolated by expression cloning from a human ovarian cancer is a mutant of TC21. The present invention teaches that ras-related genes not thought to have transforming potential can contribute importantly to cancers which have been refractory to oncogene detection. The present invention teaches that another ras relative gene, R-ras, which was previously reported to lack transforming potential, has transforming capacity as well. Thus, these and other genes similarly related to prototype and activated by analogous mechanisms may be important in the diagnosis and prognosis of certain cancers, as well as be critical in the design of rational approaches to therapy of cancers in which they play a role.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: August 11, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stuart A. Aaronson, Andrew Chan, Toru Miki
  • Patent number: 5595895
    Abstract: A highly efficient genetic cloning system is disclosed which is particularly useful for cloning cDNA copies of eukaryotic mRNAs and can direct the orientation of inserts in .lambda.-plasmid composite vectors with large cloning capacities. Cleavage of such vector DNA, by the restriction enzyme SfiI, for example, creates two different non-symmetrical 3' extensions at the ends of vector DNA. Using a linker-primer and an adaptor, cDNA is prepared to have two different sticky ends which can be ligated to those of the vector. When the cDNA fragments and the vector DNAs are mixed, both the molecules can assemble without self-circularization due to base-pairing specificity. This system provides (1) high cloning efficiency (10.sup.7 -10.sup.8 clones/.mu.g poly(A).sup.
    Type: Grant
    Filed: June 24, 1992
    Date of Patent: January 21, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Toru Miki, Stuart A. Aaronson
  • Patent number: 5512434
    Abstract: A method for the identification of related polypeptides, using an function-based selection criterion, is disclosed. A novel human phosphatase, and nucleotide sequences coding therefor, identified by the aforementioned method and designated VHR, is also disclosed.
    Type: Grant
    Filed: December 14, 1992
    Date of Patent: April 30, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stuart A. Aaronson, Donald P. Bottaro, Toshio Ishibashi, Toru Miki